Ipsen S.A. (IPN) Earnings Call Transcripts

Ipsen S.A.'s Latest Earnings Call - May 18, 2026

In the Q1 2026 earnings call for Ipsen S.A., management highlighted the promising Phase II results for corabotase, a first-in-class recombinant neuroinhibitor targeting aesthetic applications. The trial demonstrated a 66% response rate at week 4 for patients treated with corabotase compared to 0% for placebo, indicating strong efficacy. Revenue and earnings figures were not disclosed in the call, but management expressed optimism about ongoing clinical trials and the potential for corabotase to reshape the market for neurotoxins. Guidance for the upcoming quarters remains positive as Ipsen anticipates multiple readouts from their neuroscience pipeline over the next three years.

Reported metrics

Guidance from management

Management is optimistic about the upcoming Phase III trials and expects multiple readouts from their neuroscience programs over the next three years, indicating a strong pipeline ahead.

What management said

Maybe I'll start addressing this question. So the first one is a question regarding abobotulinum A in our trial. So I'd like to start by saying it's not really possible to compare data from the Phase III registrational trial run with Dysport in 2007, where they were 100 patients treated with our active comparator arm in a Phase II proof of concept. So there are many differences between those two studies. And one key ...

Thank you for this complementary answer, Professor Kerscher. To the other part of your question regarding the duration of action, I would say the detailed comparison at isolated late time points should really be interpreted with caution. The study was not powered for that level of granularity and the sample size are limited. The more meaningful comparison is across the duration window, where we see a very clear and ...

What analysts pressed on

Analysts expressed concerns regarding the small sample size of the Phase II trial and the implications of prior botulinum toxin exposure on patient outcomes. There were questions about how these factors might affect the broader applicability of the results in real-world settings.

Main topics on the call

• Corabotase Efficacy — The Phase II LANTIC trial showed that 66% of patients treated with corabotase achieved at least a 2-grade improvement in glabellar lines at week 4, compared to 0% for placebo. Professor Kerscher noted, "This is a high pe...
• Safety Profile of Corabotase — The safety profile of corabotase was reported as consistent with existing botulinum toxin A products, with no significant adverse events noted during the trial. Kerscher stated, "Corabotase was very much tolerated, absol...
• Phase III Trials Initiation — Ipsen has commenced parallel Phase III trials for corabotase based on the positive Phase II results, indicating strong confidence in the product's potential. Management stated, "We are really encouraged and have started ...
• Patient Satisfaction — Patient satisfaction remained high over a prolonged period, with Kerscher highlighting that satisfaction levels were maintained for up to 32 weeks post-treatment. "Patients have clearly shown that they are satisfied over...

Read the full Ipsen S.A. transcript (May 18, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 38 Ipsen S.A. earnings call transcripts on record, spanning January 15, 2020 to July 30, 2026. Based on this history, Ipsen S.A. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IPN

Exchange

ENXTPA

Country

FR

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

38

First call

January 15, 2020

Most recent

July 30, 2026

Reporting cadence

quarterly